Neurocrine Biosciences (NBIX) Non-Current Deffered Revenue (2010 - 2018)

Neurocrine Biosciences (NBIX) has reported Non-Current Deffered Revenue for 9 consecutive years, with $18.1 million the latest figure, recorded in Q4 2018.

• For the quarter ending Q4 2018, Non-Current Deffered Revenue rose 77.05% year-over-year to $18.1 million; the trailing twelve-month figure through Dec 2018 stood at $18.1 million (up 77.05% YoY), and the FY2018 full-year result was $18.1 million, up 77.05% from the prior year.
• Non-Current Deffered Revenue rose to $18.1 million in Q4 2018 per NBIX's latest filing, from $12.1 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $18.1 million in Q4 2018 and bottomed at $10.2 million in Q1 2016.
• Historically, Non-Current Deffered Revenue has averaged $12.2 million across 5 years, with a median of $10.6 million in 2015.
• The sharpest annual moves came in 2016 and 2018: Non-Current Deffered Revenue retreated 24.03% in 2016, then jumped 77.05% in 2018.
• Over 5 years, Non-Current Deffered Revenue stood at $14.3 million in 2014, then fell by 23.91% to $10.9 million in 2015, then fell by 6.12% to $10.2 million in 2016, then changed by 0.0% to $10.2 million in 2017, then surged by 77.05% to $18.1 million in 2018.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $18.1 million, $12.1 million, and $10.2 million for Q4 2018, Q3 2018, and Q2 2018 respectively.